Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
$2.20
-2.7%
$3.02
$1.84
$5.31
$75.61M1.51260,801 shs817,661 shs
Dominari Holdings Inc. stock logo
DOMH
Dominari
$5.27
+0.4%
$5.24
$0.83
$13.58
$77.17M0.61272,657 shs72,855 shs
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$1.91
+4.3%
$1.82
$1.33
$2.89
$55.59M1.75412,266 shs180,983 shs
Vical Incorporated stock logo
VICL
Vical
$1.24
$0.60
$1.47
$21.01M0.321.44 million shs35,024 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
0.00%-1.35%-37.68%+0.92%-51.22%
Dominari Holdings Inc. stock logo
DOMH
Dominari
0.00%-5.05%+8.44%+45.18%+162.19%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
0.00%+4.89%+1.54%+25.59%+8.47%
Vical Incorporated stock logo
VICL
Vical
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
1.1487 of 5 stars
3.80.00.00.00.60.00.6
Dominari Holdings Inc. stock logo
DOMH
Dominari
0.3546 of 5 stars
0.02.00.00.00.02.50.6
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
2.1335 of 5 stars
3.51.00.00.00.63.30.6
Vical Incorporated stock logo
VICL
Vical
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
3.50
Strong Buy$14.33551.52% Upside
Dominari Holdings Inc. stock logo
DOMH
Dominari
0.00
N/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
3.00
Buy$21.001,000.05% Upside
Vical Incorporated stock logo
VICL
Vical
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
N/AN/AN/AN/A$0.61 per shareN/A
Dominari Holdings Inc. stock logo
DOMH
Dominari
$18.15M4.25N/AN/A$5.71 per share0.92
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$57.67M0.98N/AN/A($0.06) per share-31.82
Vical Incorporated stock logo
VICL
Vical
$1.62M0.00N/AN/A$1.82 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
-$39.83M-$1.34N/AN/AN/AN/A-176.11%-103.32%8/12/2025 (Estimated)
Dominari Holdings Inc. stock logo
DOMH
Dominari
-$14.70M-$4.50N/AN/A-167.73%-91.67%-77.80%8/6/2025 (Estimated)
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$46M-$2.23N/AN/AN/A-71.24%-4,712.53%-27.67%8/12/2025 (Estimated)
Vical Incorporated stock logo
VICL
Vical
-$16.25M-$0.81N/AN/AN/A-1,002.10%-29.46%-27.85%N/A

Latest VICL, ACHV, DOMH, and FBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
-$0.37-$0.37N/A-$0.37N/AN/A
4/15/2025Q4 2024
Dominari Holdings Inc. stock logo
DOMH
Dominari
N/A$0.20N/A$0.20N/A$6.56 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
N/AN/AN/AN/AN/A
Dominari Holdings Inc. stock logo
DOMH
Dominari
N/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/AN/AN/AN/AN/A
Vical Incorporated stock logo
VICL
Vical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
0.85
3.51
3.51
Dominari Holdings Inc. stock logo
DOMH
Dominari
N/A
5.74
5.74
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
1.74
1.72
1.55
Vical Incorporated stock logo
VICL
Vical
N/A
36.84
36.84

Institutional Ownership

CompanyInstitutional Ownership
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
33.52%
Dominari Holdings Inc. stock logo
DOMH
Dominari
42.48%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
96.51%
Vical Incorporated stock logo
VICL
Vical
29.06%

Insider Ownership

CompanyInsider Ownership
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
3.00%
Dominari Holdings Inc. stock logo
DOMH
Dominari
32.98%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
27.90%
Vical Incorporated stock logo
VICL
Vical
4.58%
CompanyEmployeesShares OutstandingFree FloatOptionable
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
2034.69 million33.64 millionOptionable
Dominari Holdings Inc. stock logo
DOMH
Dominari
414.64 million9.81 millionNot Optionable
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
17029.57 million21.32 millionOptionable
Vical Incorporated stock logo
VICL
Vical
3022.84 millionN/ANot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Achieve Life Sciences stock logo

Achieve Life Sciences NASDAQ:ACHV

$2.20 -0.06 (-2.65%)
Closing price 07/3/2025 03:53 PM Eastern
Extended Trading
$2.15 -0.05 (-2.05%)
As of 07/3/2025 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Dominari stock logo

Dominari NASDAQ:DOMH

$5.27 +0.02 (+0.38%)
As of 07/3/2025 01:00 PM Eastern

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

Fortress Biotech stock logo

Fortress Biotech NASDAQ:FBIO

$1.91 +0.08 (+4.32%)
As of 07/3/2025 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Vical stock logo

Vical NASDAQ:VICL

Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.